Filters

Randi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, Vincent Des Portes, Andrew Stanfield, Barbara Koumaras, Gerd Rosenkranz, Alessandra Murgia, Christian Wolf, George Apostol, Florian von Raison

Scientific reports 2019;8(1):16970

Free Full Text

Abstract

Evaluation of Operational Models of Agonism and Allosterism at Receptors with Multiple Orthosteric Binding Sites.

Karen J Gregory, Jesús Giraldo, Jiayin Diao, Arthur Christopoulos, Katie Leach

Molecular pharmacology 2020;97(1):35-45

Full Text

Abstract

Shining Light on an mGlu5 Photoswitchable NAM: A Theoretical Perspective.

James A R Dalton, Isaias Lans, Xavier Rovira, Fanny Malhaire, Xavier Gómez-Santacana, Silvia Pittolo, Pau Gorostiza, Amadeu Llebaria, Cyril Goudet, Jean-Philippe Pin, Jesús Giraldo

Current neuropharmacology 2017;14(5):441-54

Free Full Text

Abstract

18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry.

Dean F Wong, Rikki Waterhouse, Hiroto Kuwabara, Jongho Kim, James R Brašić, Wichana Chamroonrat, Michael Stabins, Daniel P Holt, Robert F Dannals, Terence G Hamill, P David Mozley

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013;54(3):388-96

Free Full Text

Abstract

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.

Daniela Berg, Jana Godau, Claudia Trenkwalder, Karla Eggert, Iiona Csoti, Alexander Storch, Heiko Huber, Monica Morelli-Canelo, Maria Stamelou, Vincent Ries, Martin Wolz, Christine Schneider, Thérèse Di Paolo, Fabrizio Gasparini, Sam Hariry, Marc Vandemeulebroecke, Walid Abi-Saab, Katy Cooke, Donald Johns, Baltazar Gomez-Mancilla

Movement disorders : official journal of the Movement Disorder Society 2011;26(7):1243-50

Full Text

Abstract

Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.

Rama Sivasubramanian, Abhijit Chakraborty, Marie-Laure Rouzade-Dominguez, Srikanth Neelakantham, Annamaria Jakab, Tjeert Mensinga, Eric Legangneux, Ralph Woessner, Mike Ufer

International journal of clinical pharmacology and therapeutics 2015;53(7):550-6

Full Text

Abstract

Results: 1 – 15 / 18

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Receptor, Metabotropic Glutamate 5""[mesh_terms]

Mechanisms Underlying Allosteric Molecular Switches of Metabotropic Glutamate Receptor 5.

Facile F labeling of non-activated arenes via a spirocyclic iodonium(III) ylide method and its application in the synthesis of the mGluR PET radiopharmaceutical [F]FPEB.

Computational analysis of negative and positive allosteric modulator binding and function in metabotropic glutamate receptor 5 (in)activation.

Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.

Structural insight to mutation effects uncover a common allosteric site in class C GPCRs.

Biodistribution and radiation dosimetry of a positron emission tomographic ligand, 18F-SP203, to image metabotropic glutamate subtype 5 receptors in humans.

Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.

Medical treatment of GORD. Emerging therapeutic targets and concepts.

Regulation of the mGluR5, EAAT1 and GS expression by glucocorticoids in MG-63 osteoblast-like osteosarcoma cells.

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents.

Evaluation of Operational Models of Agonism and Allosterism at Receptors with Multiple Orthosteric Binding Sites.

Shining Light on an mGlu5 Photoswitchable NAM: A Theoretical Perspective.

18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry.

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.

Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.

Results for
""Receptor, Metabotropic Glutamate 5""[mesh_terms]